Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Genome-wide cell-free DNA fragmentation in patients with cancer.

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.

Nature. 2019 May 29. doi: 10.1038/s41586-019-1272-6. [Epub ahead of print]

PMID:
31142840
2.

"I am busy surviving" - Views about physical exercise in older adults scheduled for colorectal cancer surgery.

Agasi-Idenburg CS, Zuilen MK, Westerman MJ, Punt CJA, Aaronson NK, Stuiver MM.

J Geriatr Oncol. 2019 May 20. pii: S1879-4068(19)30035-9. doi: 10.1016/j.jgo.2019.05.001. [Epub ahead of print]

PMID:
31122871
3.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6).

Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).

BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.

4.

Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.

Steins A, Ebbing EA, Creemers A, van der Zalm AP, Jibodh RA, Waasdorp C, Meijer SL, van Delden OM, Krishnadath KK, Hulshof MCCM, Bennink RJ, Punt CJA, Medema JP, Bijlsma MF, van Laarhoven HWM.

Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32364. [Epub ahead of print]

PMID:
31018252
5.

The association between preoperative fatigue and instrumental activities in daily living with complications and length of hospital stay in patients undergoing colorectal surgery.

Agasi-Idenburg SC, Punt CJA, Aaronson NK, Stuiver MM.

Aging Clin Exp Res. 2019 Apr 17. doi: 10.1007/s40520-019-01199-2. [Epub ahead of print]

PMID:
30997661
6.

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.

Buisman FE, Homs MYV, Grünhagen DJ, Filipe WF, Bennink RJ, Besselink MGH, Borel Rinkes IHM, Bruijnen RCG, Cercek A, D'Angelica MI, van Delden OM, Donswijk ML, van Doorn L, Doornebosch PG, Emmering J, Erdmann JI, IJzerman NS, Grootscholten C, Hagendoorn J, Kemeny NE, Kingham TP, Klompenhouwer EG, Kok NFM, Koolen S, Kuhlmann KFD, Kuiper MC, Lam MGE, Mathijssen RHJ, Moelker A, Oomen-de Hoop E, Punt CJA, Te Riele WW, Roodhart JML, Swijnenburg RJ, Prevoo W, Tanis PJ, Vermaas M, Versleijen MWJ, Veuger FP, Weterman MJ, Verhoef C, Groot Koerkamp B.

BMC Cancer. 2019 Apr 5;19(1):327. doi: 10.1186/s12885-019-5515-6.

7.

Keeping track of all ongoing colorectal cancer trials using a mobile application: Usability and satisfaction results of the Dutch Colorectal Cancer Group Trials application.

Huiskens J, Gałek-Aldridge MS, Bakker JM, Olthof PB, van Gulik TM, Punt CJA, van Oijen MGH.

J Clin Transl Res. 2018 Dec 16;3(Suppl 3):435-440. eCollection 2018 Dec 17.

8.

The first steps in the evaluation of a "black-box" decision support tool: a protocol and feasibility study for the evaluation of Watson for Oncology.

Keikes L, Medlock S, van de Berg DJ, Zhang S, Guicherit OR, Punt CJA, van Oijen MGH.

J Clin Transl Res. 2018 Jul 27;3(Suppl 3):411-423. eCollection 2018 Dec 17.

9.

Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer.

Keikes L, de Vos-Geelen J, de Groot JWB, Punt CJA, Simkens LHJ, Trajkovic-Vidakovic M, Portielje JEA, Vos AH, Beerepoot LV, Hunting CB, Koopman M, van Oijen MGH.

Patient Educ Couns. 2019 Jul;102(7):1331-1335. doi: 10.1016/j.pec.2019.02.020. Epub 2019 Feb 22.

PMID:
30852117
10.

Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.

Kwakman JJM, van Werkhoven E, Simkens LHJ, van Rooijen JM, van de Wouw YAJ, Tije AJT, Creemers GM, Hendriks MP, Los M, van Alphen RJ, Polée MB, Muller EW, van der Velden AMT, van Voorthuizen T, Koopman M, Mol L, Punt CJA.

Clin Colorectal Cancer. 2019 Jun;18(2):e229-e230. doi: 10.1016/j.clcc.2019.01.002. Epub 2019 Jan 29. No abstract available.

PMID:
30782413
11.

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.

Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242. doi: 10.1073/pnas.1820459116. Epub 2019 Jan 22.

12.

Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer.

Kwakman JJM, van Kruijsdijk RCM, Elias SG, Seymour MT, Meade AM, Visseren FLJ, Punt CJA, Koopman M.

Acta Oncol. 2019 Mar;58(3):326-333. doi: 10.1080/0284186X.2018.1564840. Epub 2019 Jan 18.

13.

Inventory of oncologists' unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer.

Engelhardt EG, Révész D, Tamminga HJ, Punt CJA, Koopman M, Onwuteaka-Philipsen BD, Steyerberg EW, de Vet HCW, Coupé VMH.

BMC Med Inform Decis Mak. 2018 Dec 14;18(1):132. doi: 10.1186/s12911-018-0712-9.

14.

Levels of choline-containing compounds in normal liver and liver metastases of colorectal cancer as recorded by 1 H MRS.

Ter Voert EEGW, Heijmen L, van Asten JJA, Wright AJ, Nagtegaal ID, Punt CJA, de Wilt JHW, van Laarhoven HWM, Heerschap A.

NMR Biomed. 2019 Jan;32(1):e4035. doi: 10.1002/nbm.4035. Epub 2018 Nov 20.

PMID:
30457686
15.

Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

Trinh A, Lädrach C, Dawson HE, Ten Hoorn S, Kuppen PJK, Reimers MS, Koopman M, Punt CJA, Lugli A, Vermeulen L, Zlobec I.

Br J Cancer. 2018 Nov;119(10):1244-1251. doi: 10.1038/s41416-018-0230-7. Epub 2018 Nov 2.

PMID:
30385823
16.

Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients.

Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, IJzerman MJ, Koffijberg H.

Cancer Epidemiol. 2018 Dec;57:60-67. doi: 10.1016/j.canep.2018.09.008. Epub 2018 Oct 11.

17.

Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.

Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E, Tanis PJ, de Hingh IHJT, van der Schelling GP, Acherman Y, Leijtens JWA, Bremers AJA, Beets GL, Hoff C, Verhoef C, Marijnen CAM, de Wilt JHW; CARTS Study Group.

JAMA Surg. 2019 Jan 1;154(1):47-54. doi: 10.1001/jamasurg.2018.3752.

PMID:
30304338
18.

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT.

Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038/s41467-018-06567-6.

19.

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.

Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, Punt CJA, Koopman M, May AM.

J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):909-919. doi: 10.1002/jcsm.12337. Epub 2018 Aug 24.

20.

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands.

Uyl-de Groot CA, van Rooijen EM, Punt CJA, Pescott CP.

Health Econ Rev. 2018 Jul 17;8(1):13. doi: 10.1186/s13561-018-0197-3. Review.

21.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
22.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
23.

Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.

Goey KKH, Mahmoud R, Sørbye H, Glimelius B, Köhne CH, Sargent DJ, Punt CJA, van Oijen MGH, Koopman M.

Eur J Cancer. 2018 Jun;96:115-124. doi: 10.1016/j.ejca.2018.03.026. Epub 2018 May 2.

PMID:
29729562
24.

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J.

Oncotarget. 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13.

25.

Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.

van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M.

Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30.

PMID:
29353165
26.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

27.

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.

Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, Opdam FL, Boot H, Creemers GJ, van Rooijen JM, Los M, Vulink AJE, Schut H, van Meerten E, Baars A, Hamberg P, Kapiteijn E, Sommeijer DW, Punt CJA, Koopman M.

Int J Clin Oncol. 2018 Jun;23(3):482-489. doi: 10.1007/s10147-017-1220-0. Epub 2017 Dec 4.

28.

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB.

J Clin Oncol. 2018 Jan 20;36(3):268-275. doi: 10.1200/JCO.2017.73.7718. Epub 2017 Nov 21.

PMID:
29161204
29.

Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group.

Keikes L, van Oijen MGH, Lemmens VEPP, Koopman M, Punt CJA.

Clin Colorectal Cancer. 2018 Mar;17(1):58-64. doi: 10.1016/j.clcc.2017.10.007. Epub 2017 Nov 20.

30.

Pseudoprogression on bevacizumab treatment: tumor-dynamics in the modern era of systemic treatment for metastatic colorectal cancer.

Punt CJA, Huiskens J, van Gulik T, Engelbrecht M.

Acta Oncol. 2018 May;57(5):681-682. doi: 10.1080/0284186X.2017.1374556. Epub 2017 Nov 15. No abstract available.

PMID:
29140135
31.

Does portal vein embolization prior to liver resection influence the oncological outcomes - A propensity score matched comparison.

Huiskens J, Olthof PB, van der Stok EP, Bais T, van Lienden KP, Moelker A, Krumeich J, Roumen RM, Grünhagen DJ, Punt CJA, van Amerongen M, de Wilt JHW, Verhoef C, Van Gulik TM.

Eur J Surg Oncol. 2018 Jan;44(1):108-114. doi: 10.1016/j.ejso.2017.09.017. Epub 2017 Sep 20.

PMID:
29126672
32.

Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.

Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, Arnold D, Koopman M.

Br J Cancer. 2017 Dec 5;117(12):1768-1776. doi: 10.1038/bjc.2017.382. Epub 2017 Nov 9.

33.

Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.

Keikes L, Koopman M, Tanis PJ, Lemmens VEPP, Punt CJA, van Oijen MGH.

Eur J Cancer. 2017 Nov;86:166-177. doi: 10.1016/j.ejca.2017.08.034. Epub 2017 Oct 6. Review.

PMID:
28988017
34.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

35.

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.

Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, de Leng WWJ, Strengman E, Ten Tije AJ, Creemers GM, van der Velden A, de Jongh FE, Erdkamp FLG, Tanis BC, Punt CJA, Koopman M.

Ann Oncol. 2017 Sep 1;28(9):2128-2134. doi: 10.1093/annonc/mdx322.

PMID:
28911067
36.

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.

Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ.

Oncotarget. 2017 May 7;8(33):54434-54443. doi: 10.18632/oncotarget.17661. eCollection 2017 Aug 15.

37.

Colorectal cancer at high risk of peritoneal metastases: long term outcomes of a pilot study on adjuvant laparoscopic HIPEC and future perspectives.

Klaver CEL, Stam R, Sloothaak DAM, Crezee J, Bemelman WA, Punt CJA, Tanis PJ.

Oncotarget. 2017 Apr 17;8(31):51200-51209. doi: 10.18632/oncotarget.17158. eCollection 2017 Aug 1.

38.

Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review.

Engelhardt EG, Révész D, Tamminga HJ, Punt CJA, Koopman M, Onwuteaka-Philipsen BD, Steyerberg EW, Jansma IP, De Vet HCW, Coupé VMH.

Clin Colorectal Cancer. 2018 Mar;17(1):e1-e12. doi: 10.1016/j.clcc.2017.06.007. Epub 2017 Jun 24.

39.

Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, van Laarhoven HWM; Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group.

Acta Oncol. 2018 Feb;57(2):195-202. doi: 10.1080/0284186X.2017.1346381. Epub 2017 Jul 19.

PMID:
28723307
40.

The impact of data errors on the outcome of randomized clinical trials.

Buyse M, Squifflet P, Coart E, Quinaux E, Punt CJ, Saad ED.

Clin Trials. 2017 Oct;14(5):499-506. doi: 10.1177/1740774517716158. Epub 2017 Jun 22.

PMID:
28641461
41.

Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.

Kwakman JJM, Baars A, van Zweeden AA, de Mol P, Koopman M, Kok WEM, Punt CJA.

Eur J Cancer. 2017 Aug;81:130-134. doi: 10.1016/j.ejca.2017.05.022. Epub 2017 Jun 15. No abstract available.

PMID:
28623776
42.

Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Versteijne E, Lens E, van der Horst A, Bel A, Visser J, Punt CJA, Suker M, van Eijck CHJ, van Tienhoven G.

Strahlenther Onkol. 2017 Aug;193(8):630-638. doi: 10.1007/s00066-017-1153-6. Epub 2017 Jun 12.

43.

Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review.

Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH.

Crit Rev Oncol Hematol. 2017 Jun;114:53-62. doi: 10.1016/j.critrevonc.2017.03.028. Epub 2017 Mar 24. Review.

PMID:
28477747
44.

Ethnic differences in colon cancer care in the Netherlands: a nationwide registry-based study.

Lamkaddem M, Elferink MAG, Seeleman MC, Dekker E, Punt CJA, Visser O, Essink-Bot ML.

BMC Cancer. 2017 May 4;17(1):312. doi: 10.1186/s12885-017-3241-5.

45.

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A.

Ann Oncol. 2017 Sep 1;28(9):2077-2085. doi: 10.1093/annonc/mdx191. Review.

PMID:
28430862
46.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ; ARCAD Clinical Trials Program.

J Clin Oncol. 2017 Jun 10;35(17):1929-1937. doi: 10.1200/JCO.2016.71.5771. Epub 2017 Apr 17.

47.

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.

Kwakman JJM, Simkens LHJ, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, Creemers GJM, Hendriks MP, Los M, van Alphen RJ, Polée MB, Muller EW, van der Velden AMT, van Voorthuizen T, Koopman M, Mol L, van Werkhoven E, Punt CJA.

Ann Oncol. 2017 Jun 1;28(6):1288-1293. doi: 10.1093/annonc/mdx122.

PMID:
28383633
48.

Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.

Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG).

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx015.

49.

Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.

Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ.

Eur J Cancer. 2017 May;76:93-99. doi: 10.1016/j.ejca.2017.02.009. Epub 2017 Mar 10.

PMID:
28286287
50.

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.

Franken MD, van Rooijen EM, May AM, Koffijberg H, van Tinteren H, Mol L, Ten Tije AJ, Creemers GJ, van der Velden AMT, Tanis BC, Uyl-de Groot CA, Punt CJA, Koopman M, van Oijen MGH.

Eur J Cancer. 2017 Apr;75:204-212. doi: 10.1016/j.ejca.2017.01.019. Epub 2017 Feb 24.

PMID:
28237866

Supplemental Content

Support Center